A Novel Biocompatible Nanoprobe Based on Lipoproteins for Breast Cancer Cell Imaging

Authors

1 Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

2 Iran Ministry of Health and Medical Education, Deputy Ministry for Education, Tehran, Iran

3 Cancer Institute Research Center, Tehran University of Medical Sciences, Tehran, Iran

4 Labbafinejad Medical Center, Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

5 Radiation Biology Research Center, Iran University of Medical Sciences, Tehran, Iran

Abstract

Objective(s): Contrast-enhanced magnetic resonance imaging (MRI) of breast cancer provides valuable data on the disease state of patients. Biocompatible nanoprobes are expected to play a pivotal role in medical diagnosis in the future owing to their prominent advantages. The present study aimed to introduce a novel biocompatible nanoprobe based on lipoproteins for breast cancer cell imaging.
Materials and Methods: In this study, a biocompatible nanoprobe based on high-density lipoprotein was synthesized successfully. Scanning electron microscopy (SEM), Fourier-transform infrared spectroscopy (FTIR), and dynamic light scattering (DLS) were used for material characterization, and cellular uptake and in-vitro and in-vivo imaging were investigated using the nanoprobe.
Results: The nanoprobe could significantly reduce the relaxation time in the phantom and cancer cells with no toxicity in the studied cells. In addition, the nanoprobe demonstrated proper cellular uptake in the cancer cells. The in-vivo tumor images were obtained 30, 60, and 120 minutes after the injection of the nanoprobe (5.0 µmol/kg) via the tail vein, and the results indicated that the synthesized nanoprobe could be introduced as a potential MRI contrast agent.
Conclusion: Future developments may allow the application of this nanoparticle to be used in pathological and physiological processes in preclinical models.

Keywords

References

1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2012; 62(1): 10-29.
2. Mousavi SM, Mohagheghi MA, Mousavi-Jerrahi A, Nahvijou A, Seddighi Z. Outcome of breast cancer in Iran: a study of Tehran Cancer Registry data. Asian Pac J Cancer Prev. 2008; 9(2): 275-278.
3.Raymond KN, Pierre VC. Next generation, high relaxivity gadolinium MRI agents. Bioconjug Chem. 2005; 16(1): 3-8.
4.Loomans-Kropp HA, Umar A, Cancer prevention and screening: the next step in the era of precision medicine. NPJ Precis Oncol. 2019; 3: 3.
5.Shahbazi-Gahrouei D, Moradi Khaniabadi P, Moradi Khaniabadi B, Shahbazi-Gahrouei S. Medical imaging modalities using nanoprobes for cancer diagnosis. A literature review on recent findings. J Res Med Sci. 2019; 24: 38.
6.Joan Estelrich, María Jesús Sánchez-Martín, Maria Antònia Busquets. Nanoparticles in magnetic resonance imaging: from simple to dual contrast agents. Int J Nanomedicine. 2015; 10: 1727–1741.
7.Zhang Z, Chen J, Ding L, Jin H, Lovell JF, Corbin IR, Cao W, Lo PC, Yang M, Tsao MS, Luo Q, Zheng G. HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting. Small. 2010; 6(3): 430-437.
8.Koning GA, Krijger GC. Targeted multifunctional lipid-based nanocarriers for image-guided drug delivery. Anticancer Agents Med Chem. 2007; 7(4): 425-440.
9.Shahbazi-Gahrouei D, Williams M, Rizvi S, Allen BJ. In vivo studies of Gd-DTPA-monoclonal antibody and Gd-porphyrins: potential MR imaging contrast agents for cancer. J Magn Reson Imaging. 2001; 14(2):169-174.
10.Monika A. Cywińska, Ireneusz P. Grudziński, Andrzej Cieszanowski, Michał Bystrzejewski, Magdalena Popławska. Pol J Radiol. 2011; 76(2): 28–36.
11.Luke J. Leman, Bruce E. Maryanoff, and M. Reza Ghadiri. Molecules that Mimic Apolipoprotein A-I: Potential Agents for Treating Atherosclerosis. J Med Chem. 2014; 57(6): 2169–2196.
12.Sangram Raut, Linda Mooberry, Nirupama Sabnis, Ashwini Garud, Akpedje Serena Dossou, and Andras Lacko, Reconstituted HDL: Drug Delivery Platform for Overcoming Biological Barriers to Cancer Therapy. Front Pharmacol. 2018; 9: 1154.
13.Alan T Remaley, Marcelo Amar, Dmitri Sviridov. HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications. Expert Rev Cardiovasc Ther. 2008; 6(9): 1203–1215.
14. Lacko AG, Sabnis NA, Nagarajan B, McConathy WJ. HDL as a drug and nucleic acid delivery vehicle. Front Pharmacol. 2015; 6: 247.
15.Ma X, Song Q, Gao X. Reconstituted high-density lipoproteins: novel biomimetic nanocarriers for drug delivery. Acta Pharm Sin B. 2018; 8(1): 51-63.
16.Bijsterbosch MK, Van Berkel TJ. Lactosylated high density lipoprotein: a potential carrier for the site-specific delivery of drugs to parenchymal liver cells. Mol Pharmacol. 1992; 41(2): 404-411.
17.McConathy WJ, Nair MP, Paranjape S, Mooberry L, Lacko AG. Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel. Anticancer Drugs. 2008; 19(2): 183-188.
18.Corbin IR, Ng KK, Ding L, Jurisicova A, Zheng G. Near-infrared fluorescent imaging of metastatic ovarian cancer using folate receptor-targeted high-density lipoprotein nanocarriers. Nanomedicine (Lond). 2013; 8(6): 875-890.
19.Gong M, Zhang Q, Zhao Q, Zheng J, Li Y, Wang S, Yuan Y. Development of synthetic high-density lipoprotein-based ApoA-I mimetic peptide-loaded docetaxel as a drug delivery nanocarrier for breast cancer chemotherapy. Drug Deliv. 2019; 26(1): 708-716.
20.Wang T, Subramanian C, Yu M, White PT, Kuai R, Sanchez J, Moon JJ, Timmermann BN, Schwendeman A, Cohen MS. Mimetic sHDL nanoparticles: A novel drug-delivery strategy to target triple-negative breast cancer. Surgery. 2019. pii: S0039-6060(19)30349-30356.
21.Emily E. Morin, Xiang-An Li, Anna Schwendeman. HDL in Endocrine Carcinomas: Biomarker, Drug Carrier, and Potential Therapeutic. Front Endocrinol (Lausanne). 2018; 9: 715.
22.Lacko AG, Nair M, Paranjape S, Johnso S, McConathy WJ. High density lipoprotein complexes as delivery vehicles for anticancer drugs. Anticancer Res. 2002; 22(4): 2045-2049.
23.Kenneth K. Ng, Jonathan F. Lovell, Gang Zheng. Lipoprotein-Inspired Nanoparticles for Cancer Theranostics. Acc Chem Res. 2011; 44(10): 1105–1113.
24.Yang M, Chen J, Cao W, Ding L, Ng KK, Jin H, Zhang Z, Zheng G. Attenuation of nontargeted cell-kill using a high-density lipoprotein-mimicking peptide-phospholipid nanoscaffold. Nanomedicine (Lond). 2011; 6(4): 631-641.
25. Mirzaei M, Mehravi B, Ardestani MS, Ziaee SA, Pourghasem p. In Vitro Evaluation of Gd3+-Anionic Linear Globular Dendrimer-Monoclonal Antibody: Potential Magnetic Resonance Imaging Contrast Agents for Prostate Cancer Cell Imaging. Mol Imaging Biol. 2015; 17(6): 770-776.
26.Rui M, Guo W, Ding Q, Wei X, Xu J, Xu Y. Recombinant high-density lipoprotein nanoparticles containing gadolinium-labeled cholesterol for morphologic and functional magnetic resonance imaging of the liver. Int J Nanomedicine. 2012; 7: 3751-3768.
27.Rijpkema M, Kaanders JH, Joosten FB, van der Kogel AJ, Heerschap A. Method for quantitative mapping of dynamic MRI contrast agent uptake in human tumors. J Magn Reson Imaging. 2001; 14(4): 457-463.
Nanomedicine Journal
Volume 7, Issue 1
January 2020
Pages 73-79

Files

Share

How to cite

Statistics